Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- TCS +39.8%, TLYS +21.6%, SDRL +13.7%, INTU +8.6%, TGI +7.2%, VSAT +5.4%, NM +2.2%
M&A news:
- FGL +6.3% (to be acquired by CF Corp (CFCO) for $31.10/share in cash or a total of ~$1.835 billion)
Other news:
- INO +64.8% (announces that its HIV vaccine, PENNVAX-GP, 'produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine')
- XGTI +9.8% (xG Technology entered into a purchase agreement with Lincoln Park Capital Fund and announces receipt of approx. $3 mln in new order and pre-order commitments directly resulting from their appearance at the NAB 2017 Show; upwards of 20% of these commitments have been converted into firm orders)
- SPHS +8.7% (received the regulatory clearance topsalysin for the treatment of patients with urological diseases; clinical sites can now begin dosing eligible patients in a Phase 2b study in localized prostate cancer)
- UNXL +7.9% (confirmed management and directors acquire shares in the open market)
- GLYC +7.4% (continued strength -- offering: prices 7 mln (upsized from 6 mln) common stock offering at $11.50/share)
- NAVB +6.7% (CFO disclosed purchase of 25K shares worth about $11K)
- INSY +5% (FDA approval for the final product label for Syndros oral solution)
- MGEN +3.7% (granted orphan medicinal product designation by the EC to miRagen's product candidate, MRG-106)
- NVDA +2.8% (Softbank (SFTBY) has purchased stake in NVDA, according to Bloomberg)
- MIRN +2.2% (ticking higher after Synlogic files 13D - previously announced plans to acquire Mirna)
- ADI +2.2% (likely in sympathy with NVDA)
- AEO +2% (maintains $0.125 quarterly dividend)
- HZNP +1.6% (Horizon Pharma to sell marketing rights to PROCYSBI delayed-release capsules and QUINSAIR in Europe, EMEA regions to Chiesi Farmaceutici for an upfront payment of $70 mln; co now sees FY 17 net sales of $985-1020 mln)
- AMD +1.4% (likely in sympathy with NVDA)
- STM +1.4% (likely in sympathy with NVDA)
Analyst comments:
- DSX +3.5% (upgraded to In Line from Underperform at Evercore ISI)
- X +1.8% (upgraded to Outperform from Neutral at Credit Suisse)
- DSW +1.5% (upgraded to Neutral from Negative at Susquehanna)
- STLD +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
- CBT +1.1% (upgraded to Buy from Neutral at Northcoast)